Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
AIMS: To project the number of cases with age-related macular degeneration (AMD) and the numbers with attributable sight loss in the UK in 2010-2020, taking into account the expected beneficial effect of the new anti-vascular endothelial growth factor (VEGF) therapies. METHODS: A 'system dynamics' approach was used in constructing the model to simulate the dynamics of the disease in large populations. The model computed the pool of affected cases over the simulation period, taking into account the expected demographic changes. Other determinants taken into account included: prevalence; incidence; mortality; and the expected efficacy and coverage of anti-VEGF treatment. RESULTS: In the UK, 608,213 persons in 2010 are estimated to have AMD, and this is expected to increase to 755,867 by the end of the decade. Numbers with sight loss from AMD are expected to rise from 223,224 in 2010 to 291,982 by 2020. Cases with sight loss due to neovascular AMD are expected to increase from 145,697 to 189,890 by the end of the decade. CONCLUSIONS: The model predicts that the beneficial effects of the treatment would be outweighed by the strong anticipated demographic 'ageing' effect. This reaffirms the importance of continuing efforts to develop more effective and more broadly applicable therapies for AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
The Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
Cited by
The estimated prevalence and incidence of late stage age related macular degeneration in the UK
Owen, C. G., Jarrar, Z., Wormald, R., Cook, D. G., Fletcher, A. E., & Rudnicka, A. R. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-301109 · Cited by 319
Mehta, H., Tufail, A., Daien, V., Lee, A. Y., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 265
The Neovascular Age-Related Macular Degeneration Database
Zarranz-Ventura, J., Liew, G., Johnston, R. L., Xing, W., Akerele, T., McKibbin, M., Downey, L., Natha, S., Chakravarthy, U., Bailey, C., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.026 · Cited by 103
“The proportion of second treated eyes requiring antiVEGF treatment will continue to grow at a predictable rate and will have an impact on planning capacity for service delivery and models of care.(25) In the 2014 patients (2470 eyes) followed up for at least 3 years after the first treatment (156 weeks), 456 were trea…”
Seo, S.-J., Krebs, M. P., Mao, H., Jones, K., Conners, M., & Lewin, A. S. (2012) · Experimental Eye Research · doi:10.1016/j.exer.2012.05.013 · Cited by 51
“Age-related macular degeneration (AMD) is one of the most common irreversible causes of severe loss of vision in developed countries (Cheung et al., 2011; Klein et al., 2011; Krishnan et al., 2010; Minassian et al., 2011; Rudnicka et al., 2011).”
Keenan, T. D. L., Kelly, S. P., Sallam, A., Mohamed, Q., Tufail, A., & Johnston, R. L. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303233 · Cited by 29
Metadata
- Authors
- Minassian, D. C., Reidy, A., Lightstone, A., & Desai, P.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2011-02-12
- Volume
- 95
- Issue
- 10
- Pages
- 1433-1436
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2132411155
- Cited by
- 65
- References
- 3
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy. https://app.cochat.ai/papers/10.1136/bjo.2010.195370
- The paper
- Minassian, D. C., Reidy, A., Lightstone, A., & Desai, P. (2011). Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy. British Journal of Ophthalmology. https://doi.org/10.1136/bjo.2010.195370
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.